Phosphodiesterase inhibitors vs placebo
Adverse events · primary Raynaud's phenomenon
1 finding from 1 review
- no estimate extracted3 studies · 138 participantsGRADE not reported
Findings
What do systematic reviews say?
3 questions · 3 findings · 2 reviews
No studies found 0 · 0%GRADE not reported 1 · 33.3%Very low 0 · 0%Low 0 · 0%Moderate 2 · 66.7%High 0 · 0%
Phosphodiesterase 5 inhibitors (PDE5i) vs placebo
Serious adverse events · adults with Raynaud's phenomenon (primary or secondary)
1 finding from 1 review
- Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedModerate
Phosphodiesterase 5 inhibitors (PDE5i) vs placebo
Withdrawals due to adverse events · adults with Raynaud's phenomenon (primary or secondary)
1 finding from 1 review
- Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedModerate